Product Description
SP-8008 is a novel anti-platelet compound under development by Shin Poong Pharm. Co., Ltd. in the treatment of thrombotic disease. It is a hydroxybenzoic acid derivative with a novel mechanism of action involved in anti-platelet activities without bleeding. (Sourced from: http://www.shinpoong.co.kr/en/sub3/pop.php?idx=1)
Mechanisms of Action: SIPA Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Shin Poong
Company Location: Asia Pacific
Company Founding Year: 1962
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Coronary Syndrome|Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04770194 |
SP-8008-1001 | P1 |
Completed |
Stroke|Acute Coronary Syndrome |
2020-01-23 |
2021-02-26 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|